For research use only. Not for therapeutic Use.
Vobramitamab(CAT: I040858) is a novel monoclonal antibody targeting the T-cell receptor CD3 and the tumor-associated antigen PD-L1, designed to enhance immune activation against cancer cells. As a bispecific antibody, it facilitates T-cell redirection and tumor cell killing, making it a promising candidate for immuno-oncology research. Vobramitamab is being investigated for its potential in treating various solid tumors and hematologic malignancies, offering a unique mechanism to overcome immune evasion. With high specificity and potent anti-tumor activity, it represents an innovative approach in cancer immunotherapy, advancing research in targeted and adaptive immune responses.
| CAS Number | 2490556-50-6 |
| Purity | ≥95% |
